Lupin Share Price: Formoflo-G COPD Inhaler Launch and New US FDA Approval Explained
Lupin has had a busy week. On October 6, 2026, the Mumbai-based drugmaker launched Formoflo-G MDI in India, a three-in-one inhaler for chronic obstructive pulmonary disease (COPD). Two days later, it announced a US FDA approval for a generic vitamin K injection. Yet the Lupin share price fell 3.78% on October 8, closing near the bottom of its one-year range.
What do these two developments actually mean for Lupin's business, and where does the stock stand? Here's a clear explainer. For live prices, visit the Lupin share price page on GoPocket.
Key Takeaways
- Lupin launched Formoflo-G MDI in India on October 6, 2026, after approval from the Drug Controller General of India (DCGI).
- The inhaler combines three medicines (glycopyrronium, formoterol and fluticasone propionate) and is used twice daily for moderate to severe COPD.
- On October 8, Lupin said the US FDA approved its Phytonadione Injectable Emulsion, a product with estimated US sales of about $52.3 million.
- Lupin closed at ₹1,936.90 on NSE on October 8, about 23% below its 52-week high of ₹2,529.50.
- Lupin ranks No. 2 in India's respiratory therapy segment, according to IQVIA data cited by the company.
What Is Formoflo-G MDI?
COPD is a long-term lung disease that makes breathing difficult. Patients with moderate to severe COPD are often prescribed three different medicines: two that open the airways and one that reduces inflammation. Taking three separate inhalers is tiring, and many patients skip doses.
Formoflo-G puts all three into a single metered-dose inhaler. According to The Free Press Journal, it combines glycopyrronium bromide, formoterol fumarate and fluticasone propionate. Lupin describes it as the world's first fixed-dose triple-combination metered-dose inhaler for COPD. That's the company's claim; other triple therapies already exist in India in different forms, including dry powder inhalers.
The market is large. More than 55 million people in India live with COPD, as reported by VOH Network. Lupin is already ranked No. 2 in India's respiratory segment (IQVIA, MAT March 2026), so it has the doctor relationships to push a new product.
Will it move earnings soon? Probably not much. Dalal Street Investment Journal noted that Lupin hasn't disclosed pricing or revenue expectations, and the product is unlikely to materially change near-term earnings.
The US FDA Approval for Phytonadione
On October 8, 2026, Lupin announced that the US FDA had approved its Abbreviated New Drug Application for Phytonadione Injectable Emulsion USP, 1 mg/0.5 mL, in a single-dose prefilled syringe. It's a generic version of a product made by International Medication Systems.
Phytonadione is vitamin K. It's used to treat and prevent low blood clotting caused by vitamin K deficiency, including in newborns. The reference product had estimated annual US sales of about $52.3 million (IQVIA, MAT August 2026), according to the company's release carried by BioSpace.
One thing to keep in mind: this is a crowded generic. Several other companies already sell FDA-approved versions in the US, so Lupin's share of that $52.3 million market is likely to be modest.
Lupin's Respiratory Pipeline in 2026
The two announcements fit a pattern. In May 2026, Lupin received tentative US FDA approval for Revefenacin Inhalation Solution, a generic of a COPD drug with estimated US sales of $260.7 million, as reported by Indian Pharma Post. A tentative approval means the product meets FDA standards but can't be sold yet, usually because of patents. Inhalers are harder to copy than tablets, which is why they tend to face less price competition.
Lupin Share Price: Where It Stands
| Metric | Value | Date |
|---|---|---|
| Close | ₹1,936.90 (-3.78%) | October 8, 2026 |
| Previous close | ₹2,012.90 | October 7, 2026 |
| 52-week high | ₹2,529.50 | July 16, 2026 |
| 52-week low | ₹1,900.00 | October 28, 2025 |
| Distance from 52-week high | -23.4% | – |
| Distance from 52-week low | +1.9% | – |
Source: NSE bhavcopy data.
Lupin is now trading less than 2% above its 52-week low. The stock has given up all of its gains from the July peak. Pharma stocks broadly were mixed on October 8, and Lupin's fall came on a day of weak markets overall.
Promoters held 46.85% of Lupin as of June 30, 2026, per NSE filings. The company paid a final dividend of ₹18 per share in July 2026 (ex-date July 17).
What to Watch Next
- Q2 FY27 results: US sales trends and India formulations growth.
- Formoflo-G uptake: Any update on prescriptions or market share in the COPD segment.
- US launches: Timing of the Phytonadione launch and progress on Revefenacin.
- FDA inspections: Plant inspection outcomes are always a swing factor for Indian generic makers.
Track the Lupin share price and chart on GoPocket. For another pharma update this week, see our story on Sun Pharma's fundraising plan.
Sources
- The Free Press Journal, Lupin Launches Formoflo-G MDI, World's First Triple Combination Drug For COPD In India, October 6, 2026
- Dalal Street Investment Journal, Lupin launches triple-combination COPD inhaler Formoflo-G MDI in India, October 2026
- VOH Network, Lupin Launches Formoflo-G MDI, October 6, 2026
- BioSpace, Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP, October 8, 2026
- Indian Pharma Post, Lupin gets tentative FDA nod for Revefenacin inhalation solution, May 20, 2026
- NSE bhavcopy, corporate action and shareholding data for Lupin, as of October 8, 2026
Disclaimer: This article is for information and educational purposes only. It is not a recommendation to buy, sell or hold Lupin shares or any other security. Past performance does not indicate future returns. Please do your own research or consult a SEBI-registered investment adviser before investing.
